Journal List > Korean J Hematol > v.43(1) > 1032769

Lee: The Strategies for the Prevention of Chronic GVHD in Hematopoietic Stem Cell Transplantation

Abstract

Chronic graft-versus-host disease (GVHD) is the most frequent late complication after hematopoietic cell transplantation and has a major impact on the quality of life and survival. As the pathophysiology of GVHD is still incompletely understood, it has been difficult to design effective prophylactic regimens. However, prevention of acute GVHD appears to result in a lower incidence of chronic GVHD. The use of younger, non-allo-sensitized donors, preferentially of the same sex as the patient, and the use of stem cells other than G-CSF-mobilized peripheral blood stem cells, are associated with a decreased frequency of chronic GVHD. Further, the incorporation of thymoglobulin into the conditioning regimen has been demonstrated as beneficial to reduce chronic GVHD and delayed complications.

REFERENCES

1). Duell T., van Lint MT., Ljungman P, et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT working party on late effects and EULEP Study group on late effects. European group of blood and marrow transplantation. Ann Intern Med. 1997. 126:184–92.
2). Deeg HJ., Leisenring W., Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998. 91:3637–45.
crossref
3). Glucksberg H., Storb R., Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974. 18:295–304.
crossref
4). Mielcarek M., Martin PJ., Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003. 102:756–62.
crossref
5). Mielcarek M., Burroughs L., Leisenring W, et al. Prognostic relevance of “early-onset” graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation. Br J Haematol. 2005. 129:381–91.
crossref
6). Filipovich AH., Weisdorf D., Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005. 11:945–56.
7). Hess AD., Jones RJ. Autologous graft-versus-host disease. Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. 2nd ed.Boston: Blackwell Science;1999. p. 342–8.
8). Storb R., Prentice RL., Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983. 308:302–7.
9). Cutler C., Giri S., Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001. 19:3685–91.
crossref
10). Zaucha JM., Gooley T., Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001. 98:3221–7.
crossref
11). Wagner JE., Barker JN., Defor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002. 100:1611–8.
crossref
12). Sullivan KM., Agura E., Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991. 28:250–9.
13). Remberger M., Aschan J., Lönnqvist B, et al. An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. Eur J Haematol. 2001. 66:50–6.
crossref
14). Oh H., Loberiza FR Jr., Zhang MJ, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005. 105:1408–16.
crossref
15). Randolph SSB., Gooley TA., Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic cell transplants. Blood. 2004. 103:347–52.
16). Miklos DB., Kim HT., Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005. 105:2973–8.
crossref
17). Holmes JA., Whittaker JA. Histocompatibility antigen DR4 is associated with chronic graft-versus-host disease in the south Wales population. Br J Haematol. 1989. 73:424.
crossref
18). Pawelec G., Müller CA., Haen M., Ehninger G. Chronic graft-versus-host disease and HLA-DR4 in the southern German population. Br J Haematol. 1990. 75:295–6.
crossref
19). Kim HJ., Park SJ., Im HW, et al. The association of HLA antigen and GVHD in allogeneic hemopoietic stem cell transplantation with histocompatible sibling donor: a single-center experience in Korea. Int J Hematol. 2002. 76:267–71.
crossref
20). Ho VT., Mirza NQ., Junco Dd D., Okamura T., Prze-piorka D. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant. 2003. 32:771–5.
crossref
21). Jenkins MK., Schwartz RH., Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science. 1988. 241:1655–8.
crossref
22). Sakoda Y., Hashimoto D., Asakura S, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood. 2007. 109:1756–64.
crossref
23). Zhang C., Todorov I., Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006. 107:2993–3001.
crossref
24). Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol. 2004. 79:209–15.
crossref
25). Alpdogan O., Schmaltz C., Muriglan SJ, et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood. 2001. 98:2256–65.
crossref
26). Alpdogan O., Muriglan SJ., Eng JM, et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2003. 112:1095–107.
crossref
27). Sinha ML., Fry TJ., Fowler DH., Miller G., Mackall CL. Interleukin 7 worsens graft-versus-host disease. Blood. 2002. 100:2642–9.
crossref
28). Chung B., Dudl E., Toyama A, et al. IL-7 is necessary for induction of experimental graft-versus-host disease (GVHD). Blood. 2003. 102:149a, #514.
29). Weinberg K., Blazar BR., Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001. 97:1458–66.
crossref
30). Seggewiss R., Einsele H. Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation. Semin Hematol. 2007. 44:203–11.
crossref
31). Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005. 105:4200–6.
crossref
32). Ruggeri L., Capanni M., Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002. 295:2097–100.
crossref
33). Chan GW., Foss FM., Klein AK., Sprague K., Miller KB. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant. 2003. 9:753–9.
crossref
34). Chao NJ., Parker PM., Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant. 1996. 2:86–92.
35). Sokos DR., Berger M., Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002. 8:117–30.
crossref
36). Kansu E., Gooley T., Flowers ME, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood. 2001. 98:3868–70.
crossref
37). Soiffer RJ., Martin P. T-cell depletion of allogeneic hematopoietic stem cell grafts. Atkinson K, Champlin R, Ritz J, editors. Clinical bone marrow and blood stem cell transplantation. 3rd ed.Cambridge, UK: Cambridge University Press;2004. p. 416–25.
38). Wagner JE., Thompson JS., Carter SL., Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005. 366:733–41.
crossref
39). Kottaridis PD., Milligan DW., Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000. 96:2419–25.
crossref
40). Soiffer RJ., Weller E., Alyea EP, et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001. 19:1152–9.
crossref
41). Bacigalupo A., Lamparelli T., Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001. 98:2942–7.
crossref
42). Bacigalupo A., Lamparelli T., Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006. 12:560–5.
crossref
43). Remberger M., Svahn BM., Mattsson J., Ringdén O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation. 2004. 78:122–7.
crossref
44). Remberger M., Svahn BM., Hentschke P, et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999. 24:823–30.
crossref
45). Deeg HJ., Storer BE., Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006. 12:573–84.
crossref
46). Schetelig J., Bornhäuser M., Kiehl M, et al. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation—a retrospective analysis. Bone Marrow Transplant. 2004. 33:483–90.
47). Kim HJ., Min WS., Eom KS, et al. Anti-leukemic role of acute GVHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukemia. Bone Marrow Transplant. 2007. 40:1069–74.
48). Lopez M., Clarkson MR., Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006. 17:2844–53.
49). Maury S., Mary JY., Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol. 2001. 115:630–41.
crossref
50). Cutler C., Miklos D., Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006. 108:756–62.
crossref
51). Stewart BL., Storer B., Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004. 104:3501–6.
crossref
52). Akpek G., Lee SJ., Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multi-center study. Blood. 2003. 102:802–9.
crossref
53). Lee SJ., Vogelsang G., Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003. 9:215–33.
crossref
54). Couriel D., Carpenter PA., Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant. 2006. 12:375–96.
crossref
TOOLS
Similar articles